CLINICAL TRIALS PROFILE FOR CC-90001
✉ Email this page to a colleague
Clinical Trials for CC-90001
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT02110420 ↗ | First-in-human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of CC-90001 | Completed | Celgene Corporation | Phase 1 | First-in-human study to evaluate safety, tolerability, and pharmacokinetics of single and multiple ascending doses of CC-90001 |
NCT02321644 ↗ | Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study | Completed | Celgene Corporation | Phase 1 | This is a two-part, phase 1 study to evaluate the pharmacokinetics and pharmacodynamics of multiple doses of CC-90001 and the effects of food and formulation on the pharmacokinetics of single dose CC-90001 in healthy subjects. Part 1 involves the exposure of subjects to the minimum amount of UV-B light that causes minimally perceptible skin reddening. This will take place before dosing (baseline) and 3 times more while on increasing doses of CC-90001. Punch biopsies of the exposed areas will be taken and assessed for c-Jun terminal kinase activity. Part 2 involves evaluation of changes in pharmacokinetics of 2 formulations of CC-90001 when administered in the fasted state and after a high-fat meal. |
NCT02510937 ↗ | Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis | Completed | Celgene | Phase 1 | Participation in the study will last for 3months, with a 1 month screening phase. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for CC-90001
Condition Name
Clinical Trial Locations for CC-90001
Trials by Country
Clinical Trial Progress for CC-90001
Clinical Trial Phase
Clinical Trial Sponsors for CC-90001
Sponsor Name